S&P 500   4,602.00 (+1.40%)
DOW   35,301.20 (+2.09%)
QQQ   385.88 (+0.72%)
AAPL   166.25 (+2.72%)
MSFT   323.89 (+0.27%)
FB   316.85 (+3.26%)
GOOGL   2,860.16 (+0.71%)
AMZN   3,459.39 (+2.05%)
TSLA   1,004.43 (-1.04%)
NVDA   293.72 (-4.30%)
BABA   121.92 (+8.90%)
NIO   32.05 (-0.31%)
CGC   10.12 (+1.30%)
AMD   136.88 (-4.95%)
GE   96.68 (+4.21%)
MU   82.41 (+0.97%)
T   23.48 (+0.09%)
F   19.32 (+0.94%)
DIS   150.38 (+2.85%)
PFE   52.07 (-4.05%)
AMC   28.95 (-0.21%)
ACB   5.96 (+2.41%)
BA   205.38 (+3.47%)
S&P 500   4,602.00 (+1.40%)
DOW   35,301.20 (+2.09%)
QQQ   385.88 (+0.72%)
AAPL   166.25 (+2.72%)
MSFT   323.89 (+0.27%)
FB   316.85 (+3.26%)
GOOGL   2,860.16 (+0.71%)
AMZN   3,459.39 (+2.05%)
TSLA   1,004.43 (-1.04%)
NVDA   293.72 (-4.30%)
BABA   121.92 (+8.90%)
NIO   32.05 (-0.31%)
CGC   10.12 (+1.30%)
AMD   136.88 (-4.95%)
GE   96.68 (+4.21%)
MU   82.41 (+0.97%)
T   23.48 (+0.09%)
F   19.32 (+0.94%)
DIS   150.38 (+2.85%)
PFE   52.07 (-4.05%)
AMC   28.95 (-0.21%)
ACB   5.96 (+2.41%)
BA   205.38 (+3.47%)
S&P 500   4,602.00 (+1.40%)
DOW   35,301.20 (+2.09%)
QQQ   385.88 (+0.72%)
AAPL   166.25 (+2.72%)
MSFT   323.89 (+0.27%)
FB   316.85 (+3.26%)
GOOGL   2,860.16 (+0.71%)
AMZN   3,459.39 (+2.05%)
TSLA   1,004.43 (-1.04%)
NVDA   293.72 (-4.30%)
BABA   121.92 (+8.90%)
NIO   32.05 (-0.31%)
CGC   10.12 (+1.30%)
AMD   136.88 (-4.95%)
GE   96.68 (+4.21%)
MU   82.41 (+0.97%)
T   23.48 (+0.09%)
F   19.32 (+0.94%)
DIS   150.38 (+2.85%)
PFE   52.07 (-4.05%)
AMC   28.95 (-0.21%)
ACB   5.96 (+2.41%)
BA   205.38 (+3.47%)
S&P 500   4,602.00 (+1.40%)
DOW   35,301.20 (+2.09%)
QQQ   385.88 (+0.72%)
AAPL   166.25 (+2.72%)
MSFT   323.89 (+0.27%)
FB   316.85 (+3.26%)
GOOGL   2,860.16 (+0.71%)
AMZN   3,459.39 (+2.05%)
TSLA   1,004.43 (-1.04%)
NVDA   293.72 (-4.30%)
BABA   121.92 (+8.90%)
NIO   32.05 (-0.31%)
CGC   10.12 (+1.30%)
AMD   136.88 (-4.95%)
GE   96.68 (+4.21%)
MU   82.41 (+0.97%)
T   23.48 (+0.09%)
F   19.32 (+0.94%)
DIS   150.38 (+2.85%)
PFE   52.07 (-4.05%)
AMC   28.95 (-0.21%)
ACB   5.96 (+2.41%)
BA   205.38 (+3.47%)
NASDAQ:OTLK

Outlook Therapeutics News Headlines

$1.32
-0.01 (-0.75%)
(As of 12/6/2021 12:50 PM ET)
Add
Compare
Today's Range
$1.30
$1.39
50-Day Range
$1.27
$2.28
52-Week Range
$0.93
$4.26
Volume
18,500 shs
Average Volume
2.30 million shs
Market Capitalization
$231.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.9

Media Mentions By Week



Outlook Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OTLK
News Sentiment

0.59

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OTLK Articles
This Week

5

1

OTLK Articles
Average Week

Get Outlook Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

Outlook Therapeutics (NASDAQ:OTLK) News Headlines Today

SourceHeadline
MarketBeat logoOutlook Therapeutics, Inc. (NASDAQ:OTLK) Director Acquires $13,900.00 in Stock
americanbankingnews.com - December 2 at 8:56 PM
MarketBeat logoOutlook Therapeutics, Inc. (NASDAQ:OTLK) Director Acquires $20,000,000.00 in Stock
americanbankingnews.com - December 1 at 8:18 PM
finance.yahoo.com logoOutlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
finance.yahoo.com - November 29 at 8:11 PM
benzinga.com logoThinking about buying stock in Naked Brand, Biolase, Gap, Inspira Technologies, or Outlook Therapeutics?
benzinga.com - November 24 at 5:48 PM
finance.yahoo.com logoWhat Type Of Shareholders Make Up Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Share Registry?
finance.yahoo.com - November 24 at 12:48 PM
finance.yahoo.com logoOutlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
finance.yahoo.com - November 24 at 2:46 AM
finance.yahoo.com logoOutlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
finance.yahoo.com - November 23 at 4:46 PM
MarketBeat logoReviewing Bio-Techne (NASDAQ:TECH) and Outlook Therapeutics (NASDAQ:OTLK)
americanbankingnews.com - November 23 at 1:10 AM
finance.yahoo.com logoOutlook Therapeutics to Present at the Virtual Investor Roundtable Event
finance.yahoo.com - November 10 at 9:54 AM
finance.yahoo.com logoOutlook Therapeutics to Present at the [email protected] 2021 Conference Retina Showcases
finance.yahoo.com - November 3 at 12:52 PM
finance.yahoo.com logoOutlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab
finance.yahoo.com - October 12 at 3:16 PM
nasdaq.com logoOutlook Therapeutics, Inc. (NASDAQ:OTLK) stock was sold by a number of insiders in the recent year, which isn't a positive indicator for investors
nasdaq.com - October 11 at 6:31 PM
finance.yahoo.com logoOutlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
finance.yahoo.com - October 7 at 12:33 PM
markets.businessinsider.com logoOutlook Therapeutics Reports Positive 12-Month Safety Data From Phase 3 Trial On Wet AMD
markets.businessinsider.com - September 28 at 10:01 AM
finance.yahoo.com logoOutlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
finance.yahoo.com - September 28 at 10:01 AM
finance.yahoo.com logoOutlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
finance.yahoo.com - September 21 at 8:28 AM
finance.yahoo.com logoOutlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
finance.yahoo.com - September 13 at 8:53 AM
finance.yahoo.com logoOutlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 5:45 PM
msn.com logoWeekly Stock Market Outlook 30 August to 5 September 2021: Know What May Happen in Stock Market This Week | Profit Margins to Investing Decisions
msn.com - August 30 at 7:17 AM
msn.com logoStable Outlook! Ind-Ra upgrades Yes Bank’s long-term issuer rating to ‘IND BBB’ - SIGNIFICANT IMPROVEMENT!
msn.com - August 27 at 4:29 PM
nasdaq.com logoIs Outlook Therapeutics (NASDAQ:OTLK) Weighed On By Its Debt Load?
nasdaq.com - August 26 at 4:04 PM
finance.yahoo.com logoOutlook Therapeutics (NASDAQ:OTLK) shareholder returns have been splendid, earning 198% in 1 year
finance.yahoo.com - August 26 at 4:04 PM
finance.yahoo.com logoOutlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
finance.yahoo.com - August 13 at 11:11 AM
finance.yahoo.com logoOutlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
finance.yahoo.com - August 11 at 9:48 AM
finance.yahoo.com logoOutlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
finance.yahoo.com - August 11 at 9:48 AM
finance.yahoo.com logoWhy Outlook Therapeutics Stock Surged Today
finance.yahoo.com - August 3 at 5:57 PM
msn.com logoOTLK Stock: The Huge Trial News Lifting Outlook Therapeutics
msn.com - August 3 at 12:57 PM
finance.yahoo.com logoOutlook Therapeutics Stock Soars on Positive Results for Eye Treatment
finance.yahoo.com - August 3 at 12:57 PM
markets.businessinsider.com logoOutlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients
markets.businessinsider.com - August 3 at 7:57 AM
finance.yahoo.com logoOutlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
finance.yahoo.com - August 3 at 7:57 AM
benzinga.com logoOutlook on the Flame Retardant Chemicals Global Market to 2029 - Regulations for Fire Safety are Becoming More Stringent Driving Growth
benzinga.com - July 15 at 11:42 AM
marketwatch.com logoOutlook Therapeutics Names Trenary as President, CEO >OTLK
marketwatch.com - July 7 at 2:11 PM
finance.yahoo.com logoOutlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
finance.yahoo.com - July 7 at 9:10 AM
finance.yahoo.com logoDoes Outlook Therapeutics (NASDAQ:OTLK) Have A Healthy Balance Sheet?
finance.yahoo.com - July 2 at 1:54 PM
finance.yahoo.com logoOutlook Therapeutics Announces Inclusion in the Russell 2000® Index
finance.yahoo.com - June 14 at 12:49 PM
fool.com logoOUTLOOK THERAPEUTICS INC(OTLK)
fool.com - June 10 at 12:34 AM
msn.com logoBRIEF-Outlook Therapeutics Reports Completion Of Patient Dosing In The Ons-5010 Pivotal Phase 3 Norse Two Trial
msn.com - June 8 at 1:32 PM
finance.yahoo.com logoOutlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
finance.yahoo.com - June 8 at 8:31 AM
nasdaq.com logoOutlook Therapeutics (NASDAQ:OTLK) Shareholders Have Enjoyed An Impressive 118% Share Price Gain
nasdaq.com - June 7 at 2:18 PM
sg.finance.yahoo.com logoCurrent Therapies and Emerging Drugs in the Prediabetes Pipeline Soon to Boost the Treatment Outlook
sg.finance.yahoo.com - June 2 at 8:11 PM
finance.yahoo.com logoVirtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010
finance.yahoo.com - May 27 at 12:36 PM
finance.yahoo.com logoHow Many Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Do Institutions Own?
finance.yahoo.com - May 18 at 1:19 PM
msn.com logo'Earth angels' at New Outlook Center help with cancer navigation
msn.com - May 17 at 2:19 PM
finance.yahoo.com logoOutlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
finance.yahoo.com - May 14 at 9:47 AM
finance.yahoo.com logoOutlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
finance.yahoo.com - May 12 at 10:09 AM
proactiveinvestors.com logoOutlook Therapeutics is bringing a treatment for retinal disease to the market at the right time
proactiveinvestors.com - April 29 at 2:22 PM
uk.finance.yahoo.com logoOutlook Therapeutics Stock Gives Every Indication Of Being Significantly Overvalued
uk.finance.yahoo.com - April 23 at 1:31 AM
onmsft.com logoiOS Microsoft Outlook app updates with a change to device notifications
onmsft.com - April 13 at 8:38 AM
proactiveinvestors.com logoOutlook Therapeutics 'almost complete' with pivotal Phase 3 NORSE TWO trial to treat wet AMD
proactiveinvestors.com - April 12 at 7:09 PM
finance.yahoo.com logoOutlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
finance.yahoo.com - March 31 at 12:50 PM
Get Outlook Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.